StockData
Biomerica Inc logo

Biomerica Inc (BMRA) stock

BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3049% below fair value
$1.24−0.08 (-6.44%)

Close on Nov 17, 2026Market cap $5.68MP/E –Yield –

Earnings

Biomerica's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2022
$4.60M
EPS, Q2 FY2022
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Biomerica's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2022ended Nov 30, 2021Dec 16, 2021before the open$4.60M––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Biomerica has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Biomerica puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Biomerica filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?